Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + Mycobacterium w
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous, Intradermal
01
Overview
A combination therapy consisting of **docetaxel**, a cytotoxic chemotherapy agent, and **Mycobacterium w** (also known as Mycobacterium indicus pranii or Mw), a killed mycobacterial immunomodulator. Docetaxel is a taxane that binds to and stabilizes microtubules, inhibiting mitosis and leading to cancer cell death. Mycobacterium w is a non-pathogenic mycobacterium used as an immunomodulator, thought to stimulate cell-mediated immunity via activation of T-cells and cytokine induction. This combination is explored for synergistic antitumor/immunomodulatory effects, potentially enhancing anti-cancer efficacy through both direct cytotoxicity (docetaxel) and immune system activation (Mycobacterium w).
02
Targets
TUBB (Tubulin (alpha and beta subunits))CD8A (CD8 alpha/beta Coreceptor)
Beyond the preview
Go deeper on docetaxel + Mycobacterium w.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + Mycobacterium w.